RecruitingPhase IInterventional

Phase I trial: Ocular Technology Group International

This is a brand new research study, called a Phase I trial, being conducted by Ocular Technology Group International. At this very early stage, the full details about what the study is testing and how it works are not yet available to the public. This is a common practice in early research, and more information will be shared within 30 months after the study has officially come to an end. The study is open to both men and women between the ages of 40 and 80. As a Phase I trial, it will likely be focused on understanding if a new treatment is safe and what doses might be effective, rather than directly treating a specific illness. This early research is an important step in developing new medical advances.

At a glance

Status

Recruiting

Phase

Phase I

Sponsor

CooperVision International Limited

Enrolment target

Start

20 Mar 2026

Estimated completion

31 Jul 2026

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

What is this study about?

This study, called a Phase I trial, is an early step in finding out more about a new treatment from a company called Ocular Technology Group International. When a treatment is completely new, researchers first need to carefully check if it is safe for people to use and to understand how the body reacts to it. Think of it like a very first test drive before building more cars.

Because this is such a new and early study, many of the specific details about what exactly is being tested, and for what condition, are not yet available to the public. This is quite normal for Phase I trials, as the information is often kept private in the early stages of development. However, the plan is to release all the full details within 30 months after the study has finished.

Even though the full details aren't out yet, studies like this are very important. They lay the groundwork for potential future treatments. By understanding the safety and basic effects of a new approach, researchers can decide whether to move forward with larger studies later on that eventually aim to help people with specific health problems.

Key takeaways

This is a very early-stage scientific study (Phase I).
It's exploring a new treatment from Ocular Technology Group International.
Full details about the study are not yet publicly available.
The study is for people aged 40 to 80, both men and women.
All study details will be released within 30 months after it ends.
Participating helps advance medical knowledge for the future.

Who may be eligible?

Currently, the full information about who can and cannot take part in this study isn't available to the public. This is because the Health Research Authority (HRA), the organisation that oversees health research in the UK, has agreed that these details can be kept private for now.

What we do know is that the study is open to adults who are between 40 and 80 years old. Both men and women are welcome to participate. The study will eventually share all the specific health conditions, past treatments, or other important factors that would make someone suitable or unsuitable for this trial. These details will be released within 30 months after the study has finished.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you between 40 and 80 years old?
Are you a man or a woman?
Are you able to commit to the study's requirements (once known)?
Are you interested in helping with medical research?

Answer every question to see your result.

What does participation involve?

Because this is a very early-stage trial, the full details about what taking part would involve are not yet public. We don't have information on how many visits would be needed, what kinds of assessments (like blood tests or scans) you might have, if any medication would be given, or how long the follow-up period would be. We also don't know the full total duration of your involvement in the study.

Typically, in Phase I studies, participants are closely monitored. This could mean more frequent visits and checks than in later-stage studies. All these detailed plans will be made public within 30 months after the study completely finishes.

Potential risks and benefits

Since the full details of this study are not yet public, it's not possible to list specific potential benefits or risks. Generally, in early-stage (Phase I) trials, the main 'benefit' is often contributing to scientific knowledge that could help others in the future, rather than directly improving your health condition. There are always potential risks with any new treatment, which will be thoroughly explained to participants once the details are released. It's crucial to remember that you would have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Ocular Technology Group International
City only
London, England

Common questions

What is a Phase I trial?

A Phase I trial is the very first step in testing a new treatment in people. It mainly checks if the new treatment is safe and finds the right dose, rather than focusing on how well it works yet.

Why aren't all the details public yet?

It's common for very new studies, like this one, to keep some details private at first. This is sometimes done to protect new discoveries. All information will be shared later.

Who can take part in this study?

The study is looking for men and women aged between 40 and 80 years old. More specific requirements will be made public in the future.

Will taking part benefit my health directly?

In early Phase I trials, the main benefit is usually helping scientists learn more for future patients. Direct health benefits for participants are not the main goal at this stage.

When will more information about the study be available?

All the full details about the study will be made public within 30 months after the study officially finishes.

How to find out more

Deborah Moore

dmoore@otg.co.uk +44 (0)7015665390 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.